Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study by Tanaka, Y et al.
Extended report
Ann Rheum Dis 2010;69:1286–1291. doi:10.1136/ard.2009.121491 1286
ABSTRACT
Background  Tumour necrosis factor (TNF) inhibitors 
enable tight control of disease activity in patients 
with rheumatoid arthritis (RA). Discontinuation of TNF 
inhibitors after acquisition of low disease activity (LDA) is 
important for safety and economic reasons.
Objective  To determine whether inﬂ  iximab might be 
discontinued after achievement of LDA in patients with 
RA and to evaluate progression of articular destruction 
during the discontinuation.
Methods  114 patients with RA who had received 
inﬂ  iximab treatment, and whose Disease Activity Score, 
including a 28-joint count (DAS28) was <3.2 (LDA) for 
24 weeks, were studied.
Results  The mean disease duration of the 114 patients 
was 5.9 years, mean DAS28 5.5 and mean modiﬁ  ed 
total Sharp score (mTSS) 63.3. After maintaining LDA 
for >24 weeks by inﬂ  iximab treatment, the drug was 
discontinued and DAS28 in 102 patients was evaluated 
at year 1. Fifty-six patients (55%) continued to have 
DAS28<3.2 and 43% reached DAS<2.6 at 1 year 
after discontinuing inﬂ  iximab. For 46 patients remission 
induction by Remicade in RA (RRR) failed: disease in 29 
patients ﬂ  ared within 1 year and DAS28 was >3.2 at 
year 1 in 17 patients. Yearly progression of mTSS (∆TSS) 
remained <0.5 in 67% and 44% of the RRR-achieved and 
RRR-failed groups, respectively. The estimated ∆mTSS 
was 0.3 and 1.6 and Health Assessment Questionnaire-
Disability Index was 0.174 and 0.614 in the RRR-achieved 
and RRR-failed groups, respectively, 1 year after the 
discontinuation.
Conclusion  After attaining LDA by inﬂ  iximab, 56 (55%) 
of the 102 patients with RA were able to discontinue 
inﬂ  iximab for >1 year without progression of radiological 
articular destruction.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, systemic 
inﬂ  ammatory disease that causes signiﬁ  cant mor-
bidity and mortality. The combined use of biolog-
ical agents targeting tumour necrosis factor (TNF) 
and methotrexate (MTX) has produced signiﬁ  cant 
improvements in clinical, radiographic and func-
tional outcomes that were not previously seen and 
has revolutionised the treatment goal of RA to clin-
ical remission, structural remission and functional 
remission.1–5 The next goal should be remission 
without the use of biological agents and subse-
quent drug-free remission. Although global evi-
dence of the efﬁ  cacy and safety of TNF inhibitors 
such as inﬂ  iximab has accumulated, including the 
ATTRACT study, ASPIRE study, our RECONFIRM 
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studies and many others,5–10 there is no well-estab-
lished ﬁ  rm evidence for remission free from the use 
of biological agents.
The initial report of the potential for remission 
without the use of biological agents in patients 
with RA was reported by a British group (TNF20 
study).11 The combination of inﬂ  iximab  and 
MTX in patients with early RA who had fewer 
than 12 months of symptoms provided tight con-
trol of the disease activity and a signiﬁ  cant reduc-
tion in MRI evidence of synovitis and erosions 
at 1 year. At 2 years, functional and quality of 
life beneﬁ  ts were sustained, despite withdrawal 
of inﬂ  iximab treatment. On the other hand, the 
Behandelstrategieën (BeSt) study was conducted 
to observe clinical and radiological outcomes of 
patients with early RA treated with initial inf-
liximab and MTX who discontinued inﬂ  iximab 
after achieving a sustained Disease Activity Score 
(DAS) ≤2.4. Five years after receiving inﬂ  iximab 
and MTX as initial treatment for RA, 58% of 
120 patients discontinued inﬂ  iximab  because 
of a continuous DAS ≤2.4 and 19% of patients 
have stopped all antirheumatic drugs and remain 
in clinical remission, with minimal joint damage 
progression. These ﬁ   ndings indicate that treat-
ment using inﬂ  iximab and MTX, guided by DAS, 
is an effective and tight control to maintain low 
disease activity (LDA) and may alter the course 
of early RA.12–16
Discontinuation of TNF inhibitors after acquisi-
tion of LDA is important for reasons of safety and 
economy. For instance, the problem of the incidence 
of haematological malignancy owing to the long-
term use of TNF inhibitors remains unresolved. 
In Japan a large majority of patients have to pay 
30% of their medical costs and all wish to know 
for how long biological agents must be continued, 
but we have no answer. We successfully discontinued 
inﬂ  iximab after attaining DAS-guided remission for 
>24 weeks,10 but evidence based on multicentre 
studies is needed. Reports published to date on this 
topic are conﬁ  ned to those from the BeSt study and 
TNF20 study involving only patients at an early 
stage of RA.11–16
Thus, this multicentre study was undertaken 
to seek the possibility of discontinuing inﬂ  ix-
imab after attaining DAS-guided remission and 
maintaining LDA without inﬂ  iximab, in patients 
with RA, including patients with long-established 
disease, and to evaluate progression of articular 
destruction and functional disabilities during the 
discontinuation.
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PATIENTS AND METHODS
Patients
Data and information on patients with RA fulﬁ  lling the diag-
nostic criteria of the American College of Rheumatology were 
collected from 26 centres of remission induction by Remicade in 
RA (RRR) investigator groups in Japan.17 Disease activity of indi-
vidual patients was assessed by Disease Activity Score, includ-
ing a 28-joint count (DAS28)-erythrocyte sedimentation rate 
(ESR) or DAS28-C reactive protein (CRP) that was calculated 
according to the authorised formula (http://www.das-score.nl/, 
accessed 15 February 2010).18 Since none of the patients, except 
for one, achieved LDA measured by DAS28 despite MTX or a 
combination of MTX and other disease-modifying antirheu-
matic drugs for at least 3 months, inﬂ  iximab treatment (3 mg kg, 
every 8 weeks) was administered in the investigators’ institu-
tions, according to the treatment guideline proposed by the 
Japan College of Rheumatology.17 Joint damage was assessed 
by the van der Heijde-modiﬁ  ed total Sharp score (mTSS)19 and 
for 102 patients, x-ray images of the hands and feet at baseline, 
RRR-study entry and 1 year after the study were available; these 
were evaluable for 49 patients owing to loss of the radiographs 
and/or low quality of the x-ray images.20 21 Two blinded expert 
readers independently scored articular damage and progression 
according to the mTSS scoring method. The difference between 
the two readers’ scores for each patient’s radiographs was <1% 
of the maximum mTSS score—that is, 448.9 20 21 To conﬁ  rm that 
the x-ray results of the 49 patients represented the outcomes of 
the whole group, we compared multiple background character-
istics and changes of each characteristic from baseline to RRR-
study entry between 49 patients with evaluable x-ray images 
and 53 patients without them and no signiﬁ  cant difference was 
seen between the two groups.
After patients had achieved DAS28 (ESR)<3.2 (LDA) for >24 
weeks, informed consent to discontinue inﬂ  iximab was obtained 
from 126 patients. Other criteria were that patients were con-
trolled with <5 mg/day of oral prednisolone (PSL) and were >18 
years old. Concomitant use of MTX was started in all patients, 
and the dose of MTX was determined by each attending doctor. 
Twelve patients dropped out at the screening period, and 114 
patients were enrolled in the study and discontinued inﬂ  iximab 
(ﬁ   gure 1). The demographic indicators and baseline disease 
characteristics of the 114 patients enrolled are summarised in 
table 1.
Procedures
Study protocol was a simple observation after discontinuation of 
inﬂ  iximab. The follow-up observation was monitored by symp-
toms, signs and DAS28 (ESR) every 4–13 weeks for 2 years. The 
dose of concomitant MTX was basically consistent, but tapering 
of non-steroidal anti-inﬂ  ammatory drugs and glucocorticoid was 
allowed during the study period. The primary end points were 
that after discontinuing inﬂ  iximab, DAS28 remains <3.2 (LDA) 
for 1 year and (B) yearly progression of mTSS remains <0.5 (struc-
tural remission) for 1 year. Secondary end points were DAS28 
remains <2.6 (clinical remission) for 1 year, DAS28 remains <3.2 
for 2 years, yearly progression of mTSS remains <0.5 for 2 years 
and no rescue with inﬂ  iximab for 1 or 2 years is needed, after 
discontinuing inﬂ  iximab. When a ﬂ  are-up occurred in patients 
after the discontinuation, restart of inﬂ  iximab was allowed and 
patients were categorised into the ‘RRR-failed’ group. For the 
restart of inﬂ  iximab, the same dose (3 mg/kg) and the same pre-
medication as used before the study entry were used.
Statistical analysis
Baseline characteristics of patients are summarised in table 1 using 
the mean values for continuous variables. All multivariate analyses 
were conducted using the variables gender, age, duration of dis-
ease, DAS28 (ESR) score, DAS28 (CRP) score, tender joint count 
(0–28), swollen joint count (0–28), patient global assessment of dis-
ease activity (PaGA, 0–100 mm, visual analogue scale), ESR, CRP, 
Health Assessment Questionnaire-Disability Index (HAQ-DI), 
rheumatoid factor (RF), MTX dose and PSL dose at baseline. 
Spearman correlation analyses were performed to evaluate the 
Acquired informed consent
N=126
Dropped out during 
screening period (N=12)
Enrolled in RRR
IFX was discontinued
N=114 Withdrew from study
moved from area (N=2)
other reasons (N=10) 
RRR achieved
DAS28<3.2 at year 1
IFX is still discontinued
N=56
RRR failed
IFX was regstarted within 1 year,
or DAS28≥3.2 at year 1
N=46
Figure 1  Study design and proﬁ  le. DAS28, Disease Activity Score, 
including a 28-joint count; IFX, inﬂ  iximab; RRR, remission induction by 
Remicade in rheumatoid arthritis.
Table 1  Demographic indicators and baseline disease characteristics
  Enrolled patients 
(N=114)
RRR-achieved 
(N=56)
RRR-failed 
(N=46)
p (probability 
>χ2)
Women 87 (76%)   42 (75%)   38 (83%) 0.4691
Age (years) 51.4 (20.0–73.0)   49.5±12.6   56.1±12.2 0.0053
Disease 
duration 
(years)
5.9 (0.1–38.0)     4.8±5.9     7.8±7.7 0.0238
Tender joint 
count (0–28)
8.2±6.7     8.6±7.0     7.5±5.8 0.5798
Swollen 
joint count 
(0–28)
9.0±7.2   10.1±7.7     7.6±5.8 0.1674
PaGA 
(0–100 mm, 
VAS)
50.0±23.0   50.0±24.2   49.3±23.1 0.9520
CRP (mg/dl) 2.5±3.0     2.6±2.6     2.7±3.7 0.5531
ESR (mm/h) 46.2±26.9   43.1±24.2   54.1±30.1 0.1555
DAS28 (ESR) 
score
5.5±1.2     5.5±1.4     5.6±1.1 0.9112
DAS28 (CRP) 
score
4.9±1.2     5.1±1.3     4.8±1.3 0.5486
HAQ-DI 1.0±0.7     0.9±0.6     1.2±0.7 0.1112
mTSS* 63.3 (1.0–314.0)   46.9±46.5   97.2±86.9 0.0207
RF (U/ml)  201.9±496.5   
(68.5%)
225.7±583.3 197.9±427.8 0.5190
MTX (mg/week) 7.7±2.3     7.9±1.9     7.8±2.8 0.3232
PSL (mg/day) 2.5±3.4 (45.6%)     2.4±3.5     2.8±3.5 0.5223
Data are number of patients (%) for categorical data and the means for continuous data. 
Statistical difference was assessed by non-parametric Wilcoxon t test and p (probability 
>χ2) values are shown. Values in italic indicate a signiﬁ  cant difference (p<0.05).
*Data supplied for 33 patients who achieved RRR and 16 patients for whom RRR failed.
CRP, C-reactive protein; DAS28, Disease Activity Score, including a 28-joint count; 
ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-
Disability Index; mTSS, modiﬁ  ed total Sharp score; MTX, methotrexate; PaGA, patient 
global assessment of disease activity; PSL, prednisolone; RF, rheumatoid factor; RRR, 
remission induction by Remicade in rheumatoid arthritis; VAS, visual analogue scale.
07_annrheumdis121491.indd   1287 07_annrheumdis121491.indd   1287 6/9/2010   11:01:47 AM 6/9/2010   11:01:47 AMExtended report
Ann Rheum Dis 2010;69:1286–1291. doi:10.1136/ard.2009.121491 1288
association between multivariables at RRR-study entry and DAS28 
at the primary end point (last observation carried forward) of 102 
patients. Logistic regression analysis was carried out to estimate 
DAS28 at the primary end point as dependent variables (probabil-
ity) by DAS28 at RRR entry as independent variables. A receiver 
operating characteristic (ROC) curve was developed based on 
the logistic analysis and the signiﬁ  cant cut-off point was deter-
mined from the curve. For categorical response parameters, group 
comparisons were made using a non-parametric Wilcoxon t test. 
Statistical analyses were performed using JMP software version 7 
(SAS Institute, Cary, North Carolina, USA). All reported p values 
are two sided and p values <0.05 were considered signiﬁ  cant.
RESULTS
Study end points
The demographic indicators and baseline characteristics of the 
114 patients enrolled were as follows: mean age 51.4 years, 
mean disease duration 5.9 years and mean mTSS 63.3, indicat-
ing that the population included patients with long-established 
disease, and the mean DAS28 (ESR) score was 5.5, implying 
that most patients had highly active disease (table 1). Figure 1 
shows the study proﬁ  le. After maintaining DAS28<3.2 (LDA) 
for >24 weeks by inﬂ  iximab treatment, inﬂ  iximab was discon-
tinued in 114 patients. Twelve patients withdrew because they 
moved from area (n=2) and for other reasons (n=10), and thus 
DAS28 could be evaluated in 102 patients at year 1.
Of the 102 patients, 56 patients achieved the primary end 
point having a DAS28<3.2 and remaining without inﬂ  iximab for 
1 year after the discontinuation (ﬁ  gure 2A). Thus, 55% of the 
enrolled patients met the primary end point that LDA was main-
tained for 1 year after discontinuing inﬂ  iximab. Furthermore, 
44 patients (43%) reached DAS<2.6 after the discontinuation. 
On the other hand, 29 patients ﬂ  ared within 1 year (mean dura-
tion was 6.4 months) after the discontinuation and in 17 patients 
DAS28 was >3.2 at year 1 and thus RRR failed for 46 patients 
(45%) at year 1. Re-treatment with inﬂ  iximab in 32 patients 
was effective and the majority of patients reached DAS28<3.2 
within 24 weeks (ﬁ  gure 2B). Minimal adverse reactions at infu-
sion of the agent were seen in ﬁ  ve patients only at the ﬁ  rst or 
second infusion.
To clarify the background factors related to the RRR-
achievement, multiple clinical parameters at baseline were com-
pared between patients for whom RRR was achieved and those 
for whom it failed. Patients for whom RRR was achieved were 
younger (49.5 vs 56.1), their disease duration was shorter (4.8 
vs 7.8) and mTSS was lower (46.9 vs 97.2) than for those for 
whom RRR failed. Among 56 patients who achieved RRR, 10 
patients had early RA (disease duration <1.0 year) and eight 
long-established disease (>10 years). Of 46 patients for whom 
RRR failed, eight had early RA and 12 established disease. These 
results imply that inﬂ  iximab can be discontinued in patients 
with long-established RA. In contrast, no signiﬁ  cant difference 
was seen in gender, DAS including DAS28, tender or swollen 
joint count, ESR and CRP, HAQ-DI, RF and the dose of MTX 
and PSL. Since these factors interact with one another, we analy-
sed the relationship between RRR-achievement and a series of 
clinical parameters at baseline using multivariate analysis after 
adjusting for confounding variables. No signiﬁ  cant  relations 
Figure 2  Changes of Disease Activity Score, including a 28-joint count (DAS28) in patients with remission induction by Remicade in rheumatoid 
arthritis-achieved (RRR-achieved) and patients for whom RRR failed (RRR-failed). (A) Changes of Disease Activity Score, including a 28-joint count 
(DAS28) at baseline when inﬂ  iximab (IFX) was administered, at RRR-study entry when inﬂ  iximab was discontinued and at the primary end point at 
week 52 after discontinuing IFX in 56 patients who were still satisﬁ  ed with DAS28 (erythrocyte sedimentation rate (ESR)) <3.2 at week 52, RRR-
achieved’. (B) Changes of DAS28 at baseline, at RRR entry and the end point in 46 patients whose disease activity ﬂ  ared after the discontinuation of IFX 
or DAS28 >3.2 at week 52, ‘RRR-failed’. The lower right panel shows changes of DAS28 after the restarting IFX in 32 patients for whom RRR failed.
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between RRR-achievement and age, gender, DAS28 (ESR) score, 
PaGA and CRP were found, whereas a signiﬁ  cant correlation 
was found with disease duration (p=0.0019) and serum levels of 
RF (p=0.0128) in RRR-achievement.
To determine the correlation of DAS28 at the primary end 
point with clinical parameters at RRR-study entry, univariate 
analysis of multiple variables was carried out. No signiﬁ  cant cor-
relations between DAS28 (ESR) at the primary end point and a 
series of clinical parameters were found, whereas DAS28 (ESR) 
and DAS28 (CRP) at RRR-entry were signiﬁ  cantly correlated 
with DAS28 (ESR) at the primary end point. Subsequently, logis-
tic regression analysis to estimate the probability of DAS28<3.2 
at the primary end point as dependent variable by DAS28 at 
RRR-entry as independent variable was assessed. A signiﬁ  cant 
logistic regression curve was drawn between the dependent 
and independent variables (p=0.0005) (ﬁ  gure 3A). Thus, DAS28 
at RRR-study entry had the most marked correlation with the 
maintenance of LDA for 1 year after the discontinuation. By 
reciprocal statistics, DAS28 at RRR-study entry was estimated 
as 2.22, to attain DAS28<3.2 at the end point in 50% of the 
102 patients (ﬁ  gure 3A). Furthermore, 71.4% of patients whose 
DAS28 at study entry was <2.225, a cut-off point calculated 
from the ROC curve, continued to have DAS28<3.2 for 1 year, 
whereas only 32.6% of patients whose DAS28 at RRR-entry 
was 2.225–3.2 continued to have DAS28<3.2 (ﬁ  gure 3B), indi-
cating that ‘deep remission’ was required to maintain lower dis-
ease activity for 1 year after discontinuation of inﬂ  iximab.
Structural and functional changes
From the 102 patients enrolled in the study, 49 patients were 
selected in whom both hand and feet x-ray data were avail-
able and evaluable; experts examined the structural damage 
before and after the inﬂ  iximab treatment. When the baseline 
characteristics of the 49 patients in the study were compared 
with the rest of the patients in the study with insufﬁ  cient x-ray 
data (n=53), no signiﬁ  cant difference was seen. Next, the base-
line characteristics of the 33 patients who achieved RRR and 
16 patients for whom RRR failed were compared. As described 
in table 1, disease duration was shorter and mTSS was lower 
in patients who achieved RRR than in patients for whom RRR 
failed, but yearly progression of mTSS (∆mTSS) was compa-
rable between two groups (table 2). ∆mTSS at RRR entry was 
also comparable between two groups. However, means (0.3 vs 
1.6) and medians (0.0 vs 1.5) of ∆mTSS were lower in the RRR-
achieved group than in the RRR-failed group and more patients 
in the RRR-achieved group (67%) achieved ∆mTSS<0.5, radio-
graphic remission, than patients in the RRR-failed group (44%). 
Thus, another primary end point for structural remission was 
achieved for 1 year after the discontinuation. Furthermore, 
HAQ-DI at baseline and RRR entry was comparable between 
patients for whom RRR was achieved and those for whom it 
failed, whereas HAQ-DI at the primary end point in patients 
who achieved RRR was signiﬁ  cantly lower than that in patients 
for whom RRR failed (0.174 vs 0.614) (ﬁ  gure 4).
DISCUSSION
This multicentre study was undertaken to determine the pos-
sibility of discontinuing inﬂ  iximab treatment in patients with 
RA after acquiring DAS-guided LDA, including those with long-
  established disease. Among 102 patients who could be evaluated 
at year 1, 56 patients (55%) satisﬁ  ed the primary end point by 
maintaining DAS28<3.2 (LDA) and 44 patients (43%) reached 
DAS<2.6 (remission), remaining without inﬂ  iximab at year 1 
after the discontinuation. Of the 102 patients, 83 (81.4%) were 
in clinical remission at study entry and after discontinuing inﬂ  ixi-
mab, 39/83 patients (47%) remained in remission and 10/83 
patients (12%) progressed to LDA at the primary end point.
These data are similar to those of the BeSt study. However, the 
greatest difference between the patient populations enrolled in 
the two studies is mean disease duration—0.4 years in the BeSt 
study versus 5.9 years in our RRR study.12–16 Joint destruction also 
differed between the two studies—mean mTSS 7.0 in the BeSt 
study versus 63.3 in our RRR study—suggesting that discontinu-
ation of inﬂ  iximab after reaching LDA is possible in patients with 
early RA and also in patients with long-established disease.13–15 
On the other hand, among multiple clinical parameters at base-
line, disease duration was statistically related to RRR-achievement 
by multivariate analysis and disease duration was shorter (4.8 vs 
7.8) and mTSS was lower (46.9 vs 97.2) in patients who achieved 
Figure 3  Logistic analysis of probability of Disease Activity Score, including a 28-joint count (DAS28) was <3.2 at primary end point by DAS28 at 
remission induction by Remicade in rheumatoid arthritis entry (RRR entry). (A) Logistic regression analysis to estimate DAS28 at primary end point 
as dependent variables by DAS28 at RRR entry as independent variables. The y-axis shows the probability of DAS28 <3.2 at the primary end point 
after the 52 weeks discontinuation of inﬂ  iximab and a scatter diagram of an individual patient and logistic regression curve (solid line) are shown. 
To attain DAS28 <3.2 at the end point in 50% of the 102 patients, DAS28 at RRR study entry was estimated by reciprocal statistics. (B) From the 
receiver operating characteristic curve based on the logistic regression analysis above, the cut-off point of DAS28 at RRR-study entry was 2.225. 
Subsequently, one-way analysis of DAS28 at the primary end point by DAS28 at study entry, <2.225 versus between 2.225 and 3.2, was performed 
and the statistical difference of the two groups was sought by non-parametric Wilcoxon t test (***p<0.001). ESR, erythrocyte sedimentation rate.
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RRR than in those for whom RRR failed. These results imply 
that remission free from biological agents can be more easily 
obtained in patients with shorter disease duration than in those 
with more established disease, but discontinuation of inﬂ  iximab 
is still possible even in patients with long-established RA, because 
eight patients whose disease duration was >10 years successfully 
remained without inﬂ  iximab for 1 year.
Among 102 evaluated patients, disease in 29 patients ﬂ  ared 
within 1 year, 17 patients had DAS28>3.2 at year 1 after discon-
tinuing inﬂ  iximab and 32 patients had already been re-treated 
with inﬂ  iximab. One of the major concerns of restarting inf-
liximab is the possibility of an infusion reaction after the long-
term discontinuation, partly owing to human anti-chimeric 
antibodies.22 However, minimal adverse reactions at infusion of 
the agent were seen only in ﬁ  ve patients at the ﬁ  rst or second 
infusion. Another concern is the progress of joint damage after 
discontinuation of inﬂ   iximab. However, although the yearly 
progression of mTSS at RRR-study entry was also comparable 
between two groups, means (0.3 vs 1.6) and medians (0.0 vs 1.5) 
of ∆mTSS were shorter in the RRR-achieved group than in the 
RRR-failed group. Furthermore, at year 1 after the discontinu-
ation of inﬂ  iximab, more patients in the RRR-achieved group 
(67%) tended to satisfy ∆mTSS<0.5—that is, structural remis-
sion, than those in the RRR-failed group (44%) and HAQ-DI in 
patients who achieved RRR was signiﬁ  cantly lower than that 
in patients for whom RRR failed (0.174 vs 0.614). These results 
indicate that both structural remission and functional remission 
were maintained for 1 year in patients with LDA even after dis-
continuing inﬂ  iximab.
This study also shows the signiﬁ  cance of DAS-guided tight 
control of RA in order to maintain remission free from biologi-
cal agents. There was a signiﬁ  cant correlation between DAS28 
(ESR) or DAS28 (CRP) at RRR entry and DAS28 (ESR) at year 
1 after the discontinuation of inﬂ  iximab by univariate analysis 
of multiple variables and a logistic regression analysis. Thus, 
DAS28 at RRR-study entry had the greatest correlation with 
maintenance of LDA for 1 year after discontinuation. Also, 
DAS28 at study entry was mainly inﬂ  uenced by PaGA and ESR 
among the composite measures. By reciprocal statistics, the esti-
mated DAS28 (ESR) at RRR-study entry was 2.22 (1.85–2.70), 
to attain DAS28<3.2 at the primary end point in 50% of the 
102 patients studied. Also, 71.4% of patients whose DAS28 at 
study entry was <2.225, a cut-off point calculated from ROC 
curve, remained DAS28<3.2 for 1 year, whereas only 32.6% of 
patients whose DAS28 at RRR-entry was 2.225–3.2 remained 
DAS28<3.2. These results indicate that ‘deep remission’ appears 
to be required to maintain lower disease activity for 1 year after 
discontinuation of inﬂ  iximab.
About 55% of the 102 patients, who were in an LDA state for 
>24 weeks with inﬂ  iximab and MTX treatment, could discon-
tinue inﬂ  iximab for >1 year without progression of radiological 
articular destruction or functional disturbance. These data may 
have signiﬁ  cant implications for the optimal use of expensive 
biological treatments: (a) re-treatment with inﬂ  iximab is efﬁ  -
cient and tolerable in the patients for whom RRR failed; (b) DAS-
guided monitoring is valuable to keep tight control; (c) ‘deep 
Table 2  Radiographic indicators and baseline disease characteristics
  RRR-achieved 
(N=33)
RRR-failed 
(N=16)
p (probability 
>χ2)
Baseline
   Disease  duration 
(years)
  4.7 (0.5–14.0)   8.6 (0.5–25.0) 0.0280
  DAS28 (ESR) score   5.5 (1.9–7.6)   5.7 (4.2–6.8) 0.6976
  HAQ-DI   1.0 (0.0–2.3)   1.1 (0.0–1.8) 0.6271
  mTSS 46.9 (1.0–216.5) 97.2 (6.0–314.0) 0.0207
  Bone erosion score 23.7 (0.0–127.5) 55.5 (1.5–192.5) 0.0119
   Joint  space 
narrowing score
23.2 (1.0–89.0) 41.6 (4.5–121.5) 0.0621
   Yearly  progression 
of mTSS
13.1 (0.8–51.3) 15.0 (1.0–47.8) 0.5794
RRR-entry
   Yearly  progression 
of mTSS
  1.0 (−2.9 to 10.5)   0.7 (−2.0 to 6.7) 0.5788
Primary end point
   Yearly  progression 
of mTSS
  0.3 (−3.6 to 8.5)   1.6 (–3.6 to 7.0) 0.1087
    Median of yearly 
progression of 
mTSS
  0.0   1.5 –
   Yearly  progression 
of mTSS <0.5 (%)
67 44 0.2161
Data are number of patients (%) for categorical data and the means for continuous data. 
Statistical difference was assessed by non-parametric Wilcoxon t test and p (probability 
>χ2) values were shown. Values in italic indicate a signiﬁ  cant difference (p<0.05).
DAS28, Disease Activity Score based on assessments of 28 tender and 28 swollen 
joints; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-
Disability Index; mTSS, modiﬁ  ed total Sharp score; RRR, remission induction by 
Remicade in rheumatoid arthritis.
Figure 4  Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients for whom remission induction by Remicade in rheumatoid arthritis 
failed (RRR-failed)’ and in patients for whom ‘RRR was achieved (RRR-achieved)’ at (A) baseline, (B) RRR entry and (C) the primary end point. The 
line in the box represents the median value and the upper and lower ends of the box indicate the 25th and 75th centiles of the population. Statistical 
difference was assessed by non-parametric Wilcoxon t test.
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remission’ by tight control is required to maintain discontinua-
tion of inﬂ  iximab; (d) remission free from biological agents may 
be easier to attain in patients with early RA, but is possible for 
patients with long-established disease; (e) treatment aimed at 
reaching a target of LDA is pivotal to the approach to remis-
sion free from biological agents. Finally, TNFα is not a cause 
of RA, but if appropriate treatment with inﬂ  iximab can lead to 
drug-free remission, TNF inhibitors may shut down pathologi-
cal processes and may change or modify the disease course in 
RA. Thus, a clinical and basic research approach to the ‘process-
driven disease’ of RA is warranted.
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